Paclitaxel - Angiotech

Drug Profile

Paclitaxel - Angiotech

Alternative Names: Cremophor EL-free paclitaxel - Angiotech; Eluvia; Formula PTX; Innova; Micellar paclitaxel; Paxceed; TAXUS Element; TAXUS Express2; TAXUS Liberte; TAXUS Petal; Vascular Wrap; Zilver PTX

Latest Information Update: 24 Mar 2017

Price : $50

At a glance

  • Originator Angiotech Pharmaceuticals
  • Developer Angiotech Pharmaceuticals; Boston Scientific Corporation; Broncus Technologies; Cook Medical
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Angiogenesis inhibitors; Immunosuppressants; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Coronary artery restenosis; Myocardial infarction; Vascular restenosis
  • No development reported Emphysema
  • Discontinued Alzheimer's disease; Cancer; Multiple sclerosis; Oesophageal cancer; Post-surgical adhesions; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 01 Feb 2017 Boston Scientific completes the phase II MAJESTIC trial in Vascular restenosis in New Zealand, Germany, Belgium, Austria, Australia (Intra-arterial) (NCT01820637)
  • 01 Dec 2015 Boston Scientific initiates enrolment in the phase III IMPERIAL trial for Vascular restenosis in USA (NCT02574481)
  • 28 Sep 2015 Boston Scientific plans the pivotal IMPERIAL trial for Vascular restenosis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top